Deerfield Management Company, L.P. (Series C) Bio N Tech Se Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Bio N Tech Se stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 174,500 shares of BNTX stock, worth $17.8 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
174,500
Previous 594,000
70.62%
Holding current value
$17.8 Million
Previous $47.7 Million
56.58%
% of portfolio
0.39%
Previous 1.0%
Shares
3 transactions
Others Institutions Holding BNTX
# of Institutions
358Shares Held
38.4MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$846 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$460 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$444 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$193 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$184 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $24.7B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...